122 related articles for article (PubMed ID: 34903225)
61. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
[TBL] [Abstract][Full Text] [Related]
62. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
Said M; Soliman Z; Daebes H; M El-Nahaas S; El-Serafy M
Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1189-1195. PubMed ID: 31702417
[No Abstract] [Full Text] [Related]
63. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
[TBL] [Abstract][Full Text] [Related]
64. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
65. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
[TBL] [Abstract][Full Text] [Related]
66. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study.
Bruno S; Crosignani A; Facciotto C; Rossi S; Roffi L; Redaelli A; de Franchis R; Almasio PL; Maisonneuve P
Hepatology; 2010 Jun; 51(6):2069-76. PubMed ID: 20196120
[TBL] [Abstract][Full Text] [Related]
67. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
ANRS CO13 HEPAVIH Cohort
AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
[TBL] [Abstract][Full Text] [Related]
68. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.
Thornton K; Deming P; Manch RA; Moore A; Kohli A; Gish R; Sussman NL; Khaderi S; Scott J; Mera J; Box T; Qualls C; Sedillo M; Arora S
Hepatol Int; 2016 Jul; 10(4):624-31. PubMed ID: 27098355
[TBL] [Abstract][Full Text] [Related]
69. Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
Wake T; Tateishi R; Fukumoto T; Nakagomi R; Kinoshita MN; Nakatsuka T; Sato M; Minami T; Uchino K; Enooku K; Nakagawa H; Fujinaga H; Asaoka Y; Tanaka Y; Otsuka M; Koike K
PLoS One; 2020; 15(4):e0231836. PubMed ID: 32310974
[TBL] [Abstract][Full Text] [Related]
70. Treatment of hepatitis C: a systematic review.
Kohli A; Shaffer A; Sherman A; Kottilil S
JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
[TBL] [Abstract][Full Text] [Related]
71. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
72. Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection.
Lu M; Li J; Zhang T; Rupp LB; Trudeau S; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Xu F; Boscarino JA; Schmidt MA; Vijayadeva V; Gordon SC;
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1044-1055.e3. PubMed ID: 26804385
[TBL] [Abstract][Full Text] [Related]
73. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
74. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
75. [The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus].
Nabatchikova EA; Abdurakhmanov DT; Nikulkina EN; Rozina TP; Tanaschuk EL; Nikiforova NV; Adonyeva VS; Moiseev SV
Ter Arkh; 2020 Apr; 92(2):34-42. PubMed ID: 32598716
[TBL] [Abstract][Full Text] [Related]
76. Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
Mogahed EA; El-Karaksy H; Abdullatif H; Yasin NA; Nagy A; Alem SA; Eldeen HG; El-Raziky MS
J Pediatr; 2021 Jun; 233():126-131. PubMed ID: 33577805
[TBL] [Abstract][Full Text] [Related]
77. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients.
Corchado S; López-Cortés LF; Rivero-Juárez A; Torres-Cornejo A; Rivero A; Márquez-Coello M; Girón-González JA
PLoS One; 2014; 9(7):e101760. PubMed ID: 25013899
[TBL] [Abstract][Full Text] [Related]
78. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
[TBL] [Abstract][Full Text] [Related]
79. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
80. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]